GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Danaher Corp (NYSE:DHR) » Definitions » Gross Margin %

Danaher (Danaher) Gross Margin %

: 60.27% (As of Dec. 2023)
View and export this data going back to 1986. Start your Free Trial

Gross Margin % is calculated as gross profit divided by its revenue. Danaher's Gross Profit for the three months ended in Dec. 2023 was $1,623 Mil. Danaher's Revenue for the three months ended in Dec. 2023 was $2,693 Mil. Therefore, Danaher's Gross Margin % for the quarter that ended in Dec. 2023 was 60.27%.


The historical rank and industry rank for Danaher's Gross Margin % or its related term are showing as below:

DHR' s Gross Margin % Range Over the Past 10 Years
Min: 53.23   Med: 55.75   Max: 61.44
Current: 58.74


During the past 13 years, the highest Gross Margin % of Danaher was 61.44%. The lowest was 53.23%. And the median was 55.75%.

DHR's Gross Margin % is ranked better than
64.35% of 216 companies
in the Medical Diagnostics & Research industry
Industry Median: 46.155 vs DHR: 58.74

Danaher had a gross margin of 60.27% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Danaher was 1.80% per year.


Danaher Gross Margin % Historical Data

The historical data trend for Danaher's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Danaher Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 55.74 55.98 61.44 60.76 58.74

Danaher Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.51 60.97 56.46 58.20 60.27

Competitive Comparison

For the Diagnostics & Research subindustry, Danaher's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Danaher Gross Margin % Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Danaher's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Danaher's Gross Margin % falls into.



Danaher Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Danaher's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=14034 / 23890
=(Revenue - Cost of Goods Sold) / Revenue
=(23890 - 9856) / 23890
=58.74 %

Danaher's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=1623 / 2693
=(Revenue - Cost of Goods Sold) / Revenue
=(2693 - 1070) / 2693
=60.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Danaher  (NYSE:DHR) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Danaher had a gross margin of 60.27% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Danaher Gross Margin % Related Terms

Thank you for viewing the detailed overview of Danaher's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Danaher (Danaher) Business Description

Address
2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, USA, 20037-1701
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in two segments--life sciences and diagnostics--after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
Executives
Jose-carlos Gutierrez-ramos officer: SVP, Chief Scientific Officer C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Linda Filler director 2200 PENNSYLVANIA AVE NW, SUITE 800W, WASHINGTON DC 20037
Daniel Raskas officer: VP-Corporate Development 2099 PENNSYLVANIA AVENUE, NORTHWEST, WASHINGTON DC 20006
Teri List director 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Joakim Weidemanis officer: Executive Vice President 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Walter G Lohr director DANAHER CORP, 2099 PENNSYLVANIA AVE NW 12TH FL, WASHINGTON DC 20006
Georgeann Couchara officer: SVP, Human Resources 2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Raymond C Stevens director 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Matthew Mcgrew officer: EVP & Chief Financial Officer 2200 PENNSYLVANIA AVENUE, NW, SUITE 800 W, WASHINGTON DC 20010
Jennifer Honeycutt officer: Executive Vice President 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Alan G Spoon director 1150 15TH ST NW, WASHINGTON DC 20071
Rainer Blair officer: Executive Vice President 2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Feroz Dewan director C/O ARENA HOLDINGS MANAGEMENT LLC, 119 FIFTH AVENUE - 8TH FLOOR, NEW YORK NY 10003
Mitchell P Rales director, officer: Chairman of Exec. Committee 11790 GLEN ROAD, POTOMAC MD 20854
Brian W Ellis officer: Senior Vice President - GC 2200 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20037

Danaher (Danaher) Headlines

From GuruFocus

Q4 2021 Danaher Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2021 Danaher Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Danaher Corp at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Q3 2021 Danaher Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2023 Danaher Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2022 Danaher Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Danaher Corp Annual Shareholders Meeting Transcript

By GuruFocus Research 01-22-2024

Danaher Corp Investor and Analyst Meeting Transcript

By GuruFocus Research 01-22-2024